Bank of Montreal Can Sells 75,415 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bank of Montreal Can reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,301,657 shares of the biopharmaceutical company's stock after selling 75,415 shares during the period. Bank of Montreal Can owned approximately 0.26% of Gilead Sciences worth $304,974,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $1,789,254,000. FMR LLC increased its stake in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $207,340,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in Gilead Sciences by 148.4% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 1,817,880 shares of the biopharmaceutical company's stock worth $167,209,000 after buying an additional 1,085,987 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

GILD has been the topic of several analyst reports. Cantor Fitzgerald reiterated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. BMO Capital Markets upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $2.95 during trading hours on Thursday, hitting $102.30. The company had a trading volume of 7,458,154 shares, compared to its average volume of 7,461,123. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a fifty day simple moving average of $108.17 and a 200-day simple moving average of $96.52. The firm has a market cap of $127.38 billion, a P/E ratio of 274.61, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 3.09%. Gilead Sciences's dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.